Bausch Health Companies Inc. (BHC) analyst actions
Rating and price-target actions on BHC in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the BHC overview →
2 measured BHC analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma | Press release | -1.66% | -4.05% | |
| New Analysis Indicates That a Majority of Overt Hepatic Encephalopathy (OHE) Patients May Face Delays in Treatment Initiation and Gaps During Treatment for Access to Treatment Indicated to Reduce Risk for OHE Recurrence | Press release | +0.82% | +5.86% |
Keep exploring
More BHC: earnings → · SEC filings → · BHC overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| VITAL THERAPIES (VTL) | 415 | -0.05% | 44% |
| Zai Lab Limited - American Depositary Shares (ZLAB) | 415 | 0.00% | 49% |
| Verastem, Inc. (VSTM) | 411 | -0.09% | 48% |
| Alphatec Holdings, Inc. (ATEC) | 409 | -0.18% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.